ANTITUMOR AGENT

Abstract: An antitumor agent comprising a fused composition of camphor and liver oil containing 6.5 - 7.5 percent by weight of combined iodine. A method for treating a patient suffering from tumors, comprising administering to the patient said fused compo­ sition, preferably, in a dosage of 0.5 - 30 g./day for adult is also disclosed.

Description: ANTI TUMOR AGENT This invention relates to a novel antitumor agent. Various kinds of anti tumor agents including in a broad sense an anti-cancer agent have been known. Some of these antitumor agents have been admitted to be effective to some extent -on a certain tumor out of various kinds of tumors. However, a decisive. antitumor agent has not been yet found. Under these circumstances, studies on antitumor agents having composition different from those of conventional antitumor agents have been still continued. This invention has been accomplished as a result of study on an antitumor agent having other composition than those of conventional antitumor agents. This invention resides in an antitumor agent comprising a fused mixture of camphor and liver oil containing 6.5 - 7.5 percent by weight of combined iodine. The antitumor agent of the invention shows an effect on prevention or repression of growth of various kinds of tumors. The antitumor agent of the invention particularly shows a marked effect on prevention or repression of growth of myelogenous and lymphocytic leukemia, lymphosarcoma, malignant lymphosarcoma (Hodgkin disease), carcinoma of the colon, ovarian cancer, ileocecal tumor (cancer), lung cancer, cancer of the liver and pancreas, cancer of the breast, cancer of the digestive organ and cancer of the stomach. The antitumor agent of the invention is usually administered orally. The dosage for an adult is usually within a range from 0.5 to 30 g./day, and preferably 1 to 20 g./day, the dosage being based on the effective component, that is, the fused composition of camphor and liver oil containing 6.5 - 7.5 percent by weight of combined iodine. Continuous administration of the anti tumor agent of the inventin shows a remarkable antitumor effect, and ordinarily does not cause side effects, provided that the dosage of the antitumor agent is within the above range. The effective component of the anti tumor agent of the invention, that is, the fused composition of camphor and liver oil containing 6.5 - 7.5 percent by weight of combined iodine can be prepared by, for example, the following process. Approximately 70 - 90 parts by weight (preferably approximately 75 - 85 parts by weight) of liver oil (meeting the requirements of the Japanese Pharmacopoeia) is fused by heating to approximately 180 - 230 0C (preferably approximately 200 - 220 0C and more preferably around 2100C). To this are successively added approximately 6 - 8 parts by weight (preferably approximately 6.5 - 7.5 parts by weight) of iodine (meeting the requirements of the Japanese Pharmacopoeia) and approximately 7 - 9 parts by weight (preferably approximately 7.5 - 8.5 parts by weight) of camphor (melting point: 0 210 - 213 C, purity: not less than 97 percent by weight). The mixture is sufficiently stirred under heating to obtain a homogeneous and viscous oily liquid of dark brown. After the mixture is made homogeneous, a small amount of such an alkali agent as sodium carbonate or sodium hydrogen carbonate is preferably added to the mixture. Subsequently, the oily liquid is cooled to room temperature to obtain the desired fused composition (viscous oily liquid) of camphor and liver oil containing 6.5 - 7.5 percent by weight of combined iodine. In another process, before cooling the homogeneous and viscous oily liquid of dark brown obtained in the above process to room temperature, an optional amount of creosote (meeting the requirements of Japanese Pharmacopoeia), for example, an amount of less than approximately 20 parts by weight (preferably approximately less than 10 parts by weight) is added to the oily liquid and sufficientlly stirred under heating to obtain a homogeneous mixture. In this process, still preferred is the addition of a small amount of such an alkali ag-ent as sodium carbonate or sodium hydrogen carbonate to the stirred mixture. Subsequently, the mixture is cooled to room temperature to obtain the desired agent (viscous oily liquid) for oral administation which comprises the fused composition of camphor and liver oil containing 6.5 - 7.5 percent by weight of combined iodine and creosote. Clinical examples showing the effect brought about by administration of the antitumor agent of the present invention will be described hereinunder. The antitumor agent used in each clinical example was prepared by the following process. To 80 parts by weight of liver oil (meeting the requirements of the Japanese Pharmacopoeia) heated to about 2100C were added successively 7.0 parts by weight of iodine (meeting the requirements of the Japanese Pharmacopoeia) and 8.0 parts by weight of camphor (melting point: 210 - 2130C, purity: not less than 97 percent by weight) successively under vigorous stirring to obtain a homogeneous and visous oily liquid of dark brown. Subsequently, the oily liquid was allowed to stand for cooling. At the time when the oily liquid was cooled to about 500C, 5.0 parts by weight of creosote (meeting the requirements of the Japanese Pharmacopoeia) was added. The mixture was sufficiently stirred to become homogeneous and then allowed to stand for cooling to obtain an anti tumor agent in the form of a viscous oily liquid. The so obtained anti tumor agent was a mixture of creosote and a fused composition of camphor and liver oil containing 7.0 percent by weight of combined iodine. The anti tumor agent prepared by the above process was continuously administered to the patients orally. Clinical Example 1 Patient: Female (69 years old) Condition: Carcinoma of the colon was taken out by operation. After the operation, metastasis of the tumor was observed by X-ray examination. Bleeding was also observed. Change of condition after administration of the antitumor agent: A dosage of 1.2 g. was continuously administered to the patient 4 times a day. On the about 210th day after beginning the administration, bleeding ceased and the weight of the patient increased by about 1 Kg. Reduction and disappearance of the tumor were confirmed by X-ray examination. Clinical Example 2 Patient: Female (40 years old) Condition: Ovarian cancer was taken out by operation. After the operation, metastasis of the tumor was observed by X-ray examination. Change of condition after administration of the antitumor agent: A dosage of 1.2 g. was continuously administered to the patient 4 times a day. On the about 180th day after beginning the administration, the condition of anemia was improved and the weight of the patient increased by about 6 Kg. Clinical Example 3 Patient: Male (54 years old) Condition: Ileocecal tumor (cancer, as large as a head of a child) was taken out by operation. However, a part of the tumor could not be taken out. The X-ray examination after the operation indicated growth of the tumor (as large as a fist of an adult) and metastasis of the tumor to the rectum and the back wall of the stomach. Change of condition after administration of the antitumor agent: A dosage of 1.5 g. was continuously administered to the patient 6 times a day. On the about 150th day after beginning the administration, reduction of the ileocecal tumor (cancer) was confirmed by palpation. The X-ray examination also showed reduction of the tumor (as large as a fist of a child) and disappearance of the metastasized tumors. Clinical Example 4 Patient: Female (51 years old) Condition: Cancer of the breast Change of condition after administration of the antitumor agent: A dosage of 1.2 g. was continuously administered to the patient 4 times a day. On the about 120th day after beginning the administration, the X-ray examination indicated a little growth of the tumor, but showed no metastasis to the lung, bone or other internal organs. Clinical Example 5 Patient: Female (74 years old) Condition: A lung cancer was taken out by operation. However, a part of the cancer could not be taken out. Change of condition after administration of the antitumor agent: A dosage of 1.2 g. was continuously administered to the patient 4 times a day. On the about 150th day after beginning the administration, th X-ray examination indicated no growth of the tumor which had not been taken out by the operation. Clinical Example 6 Patient: Female (32 years old) Condition: The patient was diagonosed as suffering from malignant tumor of the limph node by X-ray examination and the examination of the lymph taken out from the armpit. A noticeable swelling was observed on the arm. Change of condition after administration of the antitumor agent: A dosage of 1.2 g. was continuously administered to the patient 5 times a day. On the about 90th day after beginning of the administration, the weight of the patient increased and the swelling disappeared. The X-ray examination indicated that the tumor reduced to approximately a half size. Clinical Example 7 Patient: Male (47 years old) Condition: Inoperable cancer of the stomach Change of condition after administration of the antitumor agent: A dosage of 1.2 g. was continuously administered to the patient 5 times a day. On the about 50th day after beginning of the administration, the pain was reduced and the appetite increased. The tumor was not ascertained by palpation. Clinical Example 8 Patient: Female (30 years old) Condition: The patient was diagonosed as suffering from cancer of the stomach by X-ray and gastro-camera examinations. Change of condition after administration of the antitumor agent: A dosage of 1.2 g. was continuously administered to the patient 4 times a day. On the about 90th day after beginning the administration, anemia was improved and the weight of the patient increased by about 5 Kg. It was confirmed by X-ray examination that the tumor reduced to approximately a half size. Clinical Example 9 Patient: Female. (52 years old) Condition: The patient was diagonosed as suffering from lymphocytic leukemia for the reasons that the limphoblaets such as myelocyten and metamyelocyten were detected in the blood and that diseased cells existed in the bone marrow fluid. Change of condition after administration of the antitumor agent: A dosage of 1.2 g. was continuously administered to the patient 4 times a day. On the about 30th day after beginning the administration, myelocyten and metamyelocyten were not detected in the blood. On the about 180th day after beginning the administration, the above limphoblaets were not detected in the blood, and red blood cells remarkably increased.

Claims: Claims: 1. An antitumor agent comprising a fused composition of camphor and liver oil containing 6.5 7.5 percent by weight of combined iodine. 2. The antitumor agent as claimed in Claim 1 wherein the fused composition of camphor and liver oil containing 6.5 - 7.5 percent by weight of combined iodine is prepared by adding under stirring 6 - 8 parts by weight of iodine and 7 - 9 parts by weight of camphor to 70 - 90 parts by weight of liver oil kept under fused conditions by heating. 3. The antitumor agent as claimed in Claim 1 wherein the fused composition of camphor and liver oil containing 6.5 - 7.5 percent by weight of combined iodine is prepared by adding under stirring 6.5 - 7.5 parts by weight of iodine and 7.5 - 8.5 parts by weight of camphor to 75 - 85 parts by weight of liver oil kept under fused conditions by heating. 4. The antitumor agent as claimed in Claim 1 containing creosote in addition to the fused composition of camphor and liver oil containing 6.5 - 7.5 percent by weight of combined iodine. 5. A method for treating a patient suffering from tumors, which comprises administering to the patient an antitumor agent comprising a fused composition of camphor and liver oil containing 6.5 - 7.5 percent by weight of combined iodine. 6. The method as claimed in Claim 5, in which the dosage is within a range from 0.5 to 30 g./day for adult.

Inventors: MORI, TOKITAKA
Applicants: MORI, TOKITAKA
Application year: 1983
Main classification: A61K35
IPC codes: A61K36, A61P35, A61K35, A61K33